Skip to main
MYO
MYO logo

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo Inc. has shown a positive trajectory in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,669 units in Q2, indicating growing demand for its myoelectric orthosis products. The company's strategic focus on redirecting growth within the orthotics and prosthetics (O&P) market, which is projected to contribute approximately 22% of revenue in 2024, positions it favorably amidst the expanding Medicare market. Furthermore, the recent positive ruling from the Centers for Medicare & Medicaid Services (CMS) to include the MyoPro under Medicare Part B benefits significantly enhances the company's market potential, suggesting robust long-term growth opportunities.

Bears say

Myomo Inc has significantly lowered its 2025 revenue guidance, revising expectations from $50–53 million down to $40–42 million. The company's marketing efforts and pipeline quality have underperformed, resulting in decreased lead quality and conversion rates, which further diminishes near-term revenue prospects. Additionally, the insurance-authorized backlog has declined from 272 in Q4 to 208, signaling a concerning trend in demand for its myoelectric orthosis products.

Myomo (MYO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.